BR112018010024A8 - compostos e composições úteis no tratamento de distúrbios relacionados a ntrk - Google Patents

compostos e composições úteis no tratamento de distúrbios relacionados a ntrk

Info

Publication number
BR112018010024A8
BR112018010024A8 BR112018010024A BR112018010024A BR112018010024A8 BR 112018010024 A8 BR112018010024 A8 BR 112018010024A8 BR 112018010024 A BR112018010024 A BR 112018010024A BR 112018010024 A BR112018010024 A BR 112018010024A BR 112018010024 A8 BR112018010024 A8 BR 112018010024A8
Authority
BR
Brazil
Prior art keywords
ntrk
compounds
treatment
related disorders
compositions useful
Prior art date
Application number
BR112018010024A
Other languages
English (en)
Other versions
BR112018010024A2 (pt
Inventor
V Miduturu Chandrasekhar
L Kim Joseph
Bifulco Neil Jr
Mark Wenglowsky Steven
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of BR112018010024A2 publication Critical patent/BR112018010024A2/pt
Publication of BR112018010024A8 publication Critical patent/BR112018010024A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

a presente invenção se refere a inibidores de ntrk que compreendem uma estrutura pirazolo[1,5-4]pirimidina-3-carbonitrila. eles são ativos contra ntrk de tipo selvagem e seus mutantes resistentes.
BR112018010024A 2015-11-19 2016-11-18 compostos e composições úteis no tratamento de distúrbios relacionados a ntrk BR112018010024A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257476P 2015-11-19 2015-11-19
PCT/US2016/062731 WO2017087778A1 (en) 2015-11-19 2016-11-18 Compounds and compositions useful for treating disorders related to ntrk

Publications (2)

Publication Number Publication Date
BR112018010024A2 BR112018010024A2 (pt) 2018-11-21
BR112018010024A8 true BR112018010024A8 (pt) 2019-02-26

Family

ID=57517997

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010024A BR112018010024A8 (pt) 2015-11-19 2016-11-18 compostos e composições úteis no tratamento de distúrbios relacionados a ntrk

Country Status (18)

Country Link
US (2) US10370379B2 (pt)
EP (1) EP3377497A1 (pt)
JP (1) JP2019500328A (pt)
KR (1) KR20180081790A (pt)
CN (1) CN108431008A (pt)
AR (1) AR106756A1 (pt)
AU (1) AU2016355196A1 (pt)
BR (1) BR112018010024A8 (pt)
CA (1) CA3005741A1 (pt)
HK (1) HK1259453A1 (pt)
IL (1) IL259164A (pt)
MX (1) MX2018006195A (pt)
PH (1) PH12018501065A1 (pt)
RU (1) RU2018122089A (pt)
SG (2) SG11201803920TA (pt)
TW (1) TWI733713B (pt)
WO (1) WO2017087778A1 (pt)
ZA (1) ZA201803530B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
EP3409674B1 (en) 2013-10-17 2022-04-06 Blueprint Medicines Corporation Process for preparing compositions useful for treating disorders related to kit
JP6458023B2 (ja) 2013-10-25 2019-01-23 ブループリント メディシンズ コーポレイション 繊維芽細胞成長因子受容体の阻害剤
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
RU2744974C2 (ru) 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
TWI787018B (zh) 2015-11-02 2022-12-11 美商纜圖藥品公司 轉染過程重排之抑制劑
AU2016355196A1 (en) 2015-11-19 2018-06-21 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
ES2957233T3 (es) 2016-04-15 2024-01-15 Blueprint Medicines Corp Inhibidores de quinasa tipo receptor de activina
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
LT3773589T (lt) 2018-04-03 2024-02-12 Blueprint Medicines Corporation Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui
JP7385658B2 (ja) 2018-10-30 2023-11-22 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物、組成物、および方法
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
TW202104232A (zh) 2019-04-12 2021-02-01 美商藍印藥品公司 (s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙-1-胺之晶形及其製造方法
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5251911A (en) 1992-12-09 1993-10-12 Blake Carlton E Safety construction for passenger vehicle
WO1998014450A1 (en) 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
ES2346204T3 (es) * 2002-09-04 2010-10-13 Schering Corporation Pirazolopirimidinas adecuadas para el tratamiento de enfermedades cancerosas.
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
BRPI0509576A (pt) 2004-04-02 2007-05-29 Osi Pharm Inc composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
DK3106463T6 (da) 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CA2761074A1 (en) 2010-05-05 2011-11-10 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
US8637516B2 (en) * 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN102241678B (zh) * 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
WO2014036387A2 (en) 2012-08-31 2014-03-06 The Regents Of The University Of Colorado Methods for diagnosis and treatment of cancer
EA201590693A1 (ru) * 2012-10-05 2015-08-31 Ригель Фармасьютикалс, Инк. Ингибиторы gdf-8
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
CA2899662A1 (en) 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
RU2672910C9 (ru) * 2013-02-21 2019-06-04 Калитор Сайенсез, ЛЛС Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
WO2014139326A1 (en) 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
EP3409674B1 (en) 2013-10-17 2022-04-06 Blueprint Medicines Corporation Process for preparing compositions useful for treating disorders related to kit
JP6458023B2 (ja) 2013-10-25 2019-01-23 ブループリント メディシンズ コーポレイション 繊維芽細胞成長因子受容体の阻害剤
WO2015108328A1 (ko) * 2014-01-14 2015-07-23 주식회사 엘지생명과학 대장암 마커로서의 신규 ntrk1 융합유전자 및 이의 용도
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10233170B2 (en) * 2014-04-08 2019-03-19 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RU2708674C2 (ru) 2014-12-15 2019-12-11 СиЭмДжи ФАРМАСЬЮТИКАЛ КО., ЛТД. Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
US9981944B2 (en) 2015-02-20 2018-05-29 Rigel Pharmaceuticals, Inc GDF-8 inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
RU2744974C2 (ru) 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
TWI787018B (zh) 2015-11-02 2022-12-11 美商纜圖藥品公司 轉染過程重排之抑制劑
AU2016355196A1 (en) 2015-11-19 2018-06-21 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
ES2957233T3 (es) 2016-04-15 2024-01-15 Blueprint Medicines Corp Inhibidores de quinasa tipo receptor de activina
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Also Published As

Publication number Publication date
KR20180081790A (ko) 2018-07-17
AR106756A1 (es) 2018-02-14
WO2017087778A1 (en) 2017-05-26
ZA201803530B (en) 2021-08-25
US10370379B2 (en) 2019-08-06
BR112018010024A2 (pt) 2018-11-21
SG10201912607SA (en) 2020-02-27
RU2018122089A (ru) 2019-12-25
US20170145018A1 (en) 2017-05-25
EP3377497A1 (en) 2018-09-26
IL259164A (en) 2018-06-28
AU2016355196A1 (en) 2018-06-21
CN108431008A (zh) 2018-08-21
US20190382410A1 (en) 2019-12-19
US11059827B2 (en) 2021-07-13
PH12018501065A1 (en) 2019-01-28
JP2019500328A (ja) 2019-01-10
TW201720826A (zh) 2017-06-16
HK1259453A1 (zh) 2019-11-29
MX2018006195A (es) 2018-09-05
TWI733713B (zh) 2021-07-21
RU2018122089A3 (pt) 2019-12-30
SG11201803920TA (en) 2018-06-28
CA3005741A1 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
BR112018010024A2 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
BR112016006048A8 (pt) composições antimicrobianas
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
EP4292652A3 (en) Compounds for the treatment of glycogen storage disorders
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
SG10201804952QA (en) Glucosylceramide synthase inhibitors
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
MX2017009929A (es) Composiciones y métodos para metabolismo muscular mejorado.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2697 DE 13/09/2022.